Using a Revenue DCF model with operating margin convergence from -0.7% to a target of 13.2% over 5 years, discounted at a WACC of 9.9%, Harvard Bioscience, Inc. (HBIO) has an intrinsic value of $9.09 per share (range: $0.34 – $25.86).
Using a Revenue DCF model with operating margin convergence from -0.7% to a target of 13.2% over 5 years, discounted at a WACC of 9.9%, Harvard Bioscience, Inc. (HBIO) has an intrinsic value of $15.36 per share (range: $2.61 – $38.90).
Using the industry peer median EV/Revenue multiple (trailing + forward), Harvard Bioscience, Inc. (HBIO) has a fair value of $9.09 based on 6 comparable companies in the Medical - Instruments & Supplies industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Harvard Bioscience, Inc.HBIO | 31 | 0.8x | 0.7x |
| Retractable Technologies, Inc. | 21 | 0.5x | — |
| Femasys Inc. | 13 | 3.5x | 3.2x |
| Cosmos Health Inc. | 10 | 0.4x | 0.4x |
| Nexalin Technology, Inc. | 7 | 21.9x | 38.4x |
| NEXGEL, Inc. | 6 | 0.8x | 0.8x |
| CollPlant Biotechnologies Ltd. | 5 | 0.8x | 0.9x |
| Industry Median | 0.8x | 0.9x | |
| (*) Revenue | 87 | 94 | |
| = Enterprise Value | 67 | 85 | |
| (-) Net Debt | 36 | 36 | |
| Equity Value | 31 | 49 | |
| (/) Outstanding shares | 4 | 4 | |
| Fair Price | $7 | $11 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.